Predicting Neurotoxicity with Brain Organoids
28bio (axosim.com) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 42nd percentile of 12122 Healthcare brands.
28bio, based in New Orleans, United States, and founded in 2014, is a neurotechnology company operating at axosim.com. It integrates tissue engineering, neural interfacing, and artificial intelligence to develop human brain organoid models that replicate neurological functions such as memory, learning, and cognition. Its CNS-3D brain organoid platform is designed to predict clinical seizure liability and neurotoxicity with higher accuracy than traditional testing methods, serving pharmaceutical and biotech companies, drug discovery researchers, and toxicology teams.
| Brand Name | 28bio |
|---|---|
| Domain | axosim.com |
| Industry | Healthcare, Technology |
| Founded | 2014 |
| Headquarters | New Orleans, United States |
| Main Competitors | Emulate, Hesperos, Axion BioSystems, Charles River Laboratories (69/100), Vyant Bio (45/100), Evotec (Cyprotex) |
Moz Domain Authority 34/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Integrating tissue engineering, neural interfacing, and AI to engineer human brain models with neurological functions, including memory, learning, and cognition." (Meta description: 20 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 4 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, HubSpot.
Social footprint: verified profiles on LinkedIn, YouTube, X (Twitter), Facebook, Instagram, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
28bio's main competitors in Healthcare: Charles River Laboratories (69/100), Vyant Bio (45/100).
Sources: Brand Analyzer scan
28bio has limited AI-search visibility, scoring 30/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 45, recommendation 30). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: 28bio official site
28bio was founded in 2014. 28bio operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
28bio integrates tissue engineering, neural interfacing, and artificial intelligence to build human brain organoid models, specifically its CNS-3D platform, used to predict clinical seizure liability and neurotoxicity in drug candidates. These models aim to provide more human-relevant data than traditional animal or cell-based testing methods used in pharmaceutical research and toxicology.
Sources: 28bio official site
28bio scores 30/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: 28bio official site
28bio offers CNS-3D brain organoid models designed for neurotoxicity and seizure liability testing in drug discovery. These models combine tissue engineering, neural interfacing, and artificial intelligence to replicate neurological functions such as memory, learning, and cognition, providing pharmaceutical and biotech companies with tools to predict neurological drug effects.
Sources: 28bio official site
28bio is a neurotechnology company headquartered in New Orleans, United States, founded in 2014. It operates under the domain axosim.com and specializes in engineering human brain organoid models that replicate neurological functions like memory, learning, and cognition for use in pharmaceutical and biotech drug discovery.
Sources: 28bio official site
28bio can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: 28bio official site
28bio is known for its CNS-3D brain organoid platform, which is reported to predict clinical seizure liability with 83% sensitivity and 89% specificity, claimed to be 13 times more predictive than traditional neurotoxicity testing methods. This positions the company as a provider of advanced human-relevant models for neurological drug effect prediction.
Sources: 28bio official site
28bio's offerings are targeted at pharmaceutical and biotech companies, drug discovery researchers, and toxicology teams. These users seek more accurate, human-relevant models for predicting neurological drug effects, particularly for assessing seizure liability and neurotoxicity during preclinical drug development.
Sources: 28bio official site
28bio scores 30/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
28bio has a weak AI-visibility profile at 30/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (45/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and no llms.txt to steer AI to its best pages.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to 28bio: Axol Bioscience (75/100), AXA Partners (75/100), BAART Programs (75/100), Bahmni (75/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.